MedTrace Logo

Gold Sodium Thiomalate in Treating Patients With Advanced Non-Small Cell Lung Cancer

NCT00575393 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 17

Last updated 2018-10-09

No results posted yet for this study

Summary

RATIONALE: Gold sodium thiomalate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.

PURPOSE: This phase I trial is studying the side effects and best dose of gold sodium thiomalate in treating patients with advanced non-small cell lung cancer.

Conditions

Interventions

DRUG

gold sodium thiomalate

GENETIC

gene expression analysis

OTHER

fluorine F 18 fluorothymidine

OTHER

mass spectrometry

OTHER

pharmacological study

Sponsors & Collaborators

Principal Investigators

  • Julian Molina, MD, PhD · Mayo Clinic

Study Design

Purpose
TREATMENT

Eligibility

Min Age
18 Years
Max Age
120 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-01-25
Primary Completion
2011-06-30
Completion
2012-02-14

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00575393 on ClinicalTrials.gov